All results
307 results
-
1305-0014 (FIBRONEERTM IPF)
This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older. If they…
- Ages
- 40 Years - N/A
- Sexes
- All
-
1305-0023 (FIBRONEERTM ILD)
This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary…
- Ages
- 18 Years - N/A
- Sexes
- All
-
7089 PAL-LIVER
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators…
- Ages
- 18 Years - 120 Years
- Sexes
- All
-
A 5-year Longitudinal Observational Study of Patients With NAFL or NASH
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual…
- Ages
- 2 Years - N/A
- Sexes
- All
-
A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and…
- Ages
- 18 Years - N/A
- Sexes
- All
-
A Pilot Study of Rapid Haplotyping procedure for Personalized Dosing of Dichloroacetate (DCA) in Hea
The purpose of this study is to identify and analyze the frequency of GSTZ1 haplotypes in a healthy adult population and determine the pharmacokinetics of…
- Ages
- 18 Years - 70 Years
- Sexes
- All
-
A Study of ASP1002 in Adults for Treatment of Solid Tumors
ASP1002 is a potential new treatment for people with certain solid tumors. Before ASP1002 is available as a treatment, the researchers need to understand how…
- Ages
- 18 Years - N/A
- Sexes
- All
-
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 * early…
- Ages
- 18 Years - 130 Years
- Sexes
- All
-
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Pts w/ MIBC
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone. Bladder…
- Ages
- 18 Years - N/A
- Sexes
- All
-
A Study to Evaluate the PK, Safety, Efficacy, and PD With ATB200/AT2221 in LOPD Subjects
This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in…
- Ages
- 0 Years - 17 Years
- Sexes
- All